Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$20.85 - $29.88 $2.56 Million - $3.67 Million
-122,976 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$24.75 - $39.14 $514,404 - $813,485
-20,784 Reduced 14.46%
122,976 $3.48 Million
Q4 2020

Feb 02, 2021

BUY
$29.0 - $41.62 $964,540 - $1.38 Million
33,260 Added 30.1%
143,760 $4.7 Million
Q3 2020

Nov 05, 2020

SELL
$16.3 - $30.64 $111,068 - $208,780
-6,814 Reduced 5.81%
110,500 $3.39 Million
Q2 2020

Aug 12, 2020

BUY
$7.95 - $18.81 $324,837 - $768,576
40,860 Added 53.44%
117,314 $1.91 Million
Q1 2020

May 12, 2020

BUY
$6.45 - $14.04 $21,285 - $46,332
3,300 Added 4.51%
76,454 $761,000
Q4 2019

Jan 27, 2020

BUY
$12.97 - $15.94 $352,784 - $433,568
27,200 Added 59.19%
73,154 $1.01 Million
Q3 2019

Oct 31, 2019

BUY
$14.75 - $20.87 $214,671 - $303,741
14,554 Added 46.35%
45,954 $697,000
Q2 2019

Aug 15, 2019

SELL
$14.71 - $19.79 $1.79 Million - $2.41 Million
-121,900 Reduced 79.52%
31,400 $618,000
Q4 2018

Feb 08, 2019

BUY
$10.6 - $17.49 $1.13 Million - $1.87 Million
106,641 Added 228.55%
153,300 $2.15 Million
Q3 2018

Nov 13, 2018

BUY
$16.65 - $21.85 $328,804 - $431,493
19,748 Added 73.38%
46,659 $817,000
Q2 2018

Aug 15, 2018

SELL
$14.8 - $18.8 $219,868 - $279,292
-14,856 Reduced 35.57%
26,911 $490,000
Q1 2018

May 11, 2018

SELL
$14.5 - $23.4 $107,300 - $173,160
-7,400 Reduced 15.05%
41,767 $783,000
Q4 2017

Feb 06, 2018

BUY
$13.5 - $16.65 $346,504 - $427,355
25,667 Added 109.22%
49,167 $752,000
Q3 2017

Nov 15, 2017

BUY
$6.05 - $14.95 $142,175 - $351,325
23,500
23,500 $351,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.